Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Levamisole→

Levamisole Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
14769-73-4
Molecular formula
C11H12N2S
Molecular weight
204.29 g/mol
Drug class
Imidazothiazole anthelminticimmunomodulatory agent
Mechanism of action
The anthelmintic action involves stimulation of nematode nicotinic acetylcholine receptors, causing sustained depolarisation and spastic paralysis. Immunomodulatory effects include modulation of T-cell and phagocyte activity.
Indications / reported uses
  • Anthelmintic treatment of susceptible nematode infections in jurisdictions where levamisole remains authorised.
  • Historical immunomodulatory use as an adjunct in selected oncology regimens; this is not a general current indication.

Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/levamisole-hydrochloride

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Levamisole Environmental Risk Assessment (ERA) (the Levamisole ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.